Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.

作者信息

Shaikh Saad

出版信息

Indian J Ophthalmol. 2008 May-Jun;56(3):259. doi: 10.4103/0301-4738.40380.

DOI:10.4103/0301-4738.40380

PMID:18417840

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2636113/

Abstract

摘要

相似文献

[1]

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.

Indian J Ophthalmol. 2008

[2]

Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.

Acta Ophthalmol Scand. 2006-12

[3]

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.

Retina. 2006-3

[4]

Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).

Clin Exp Ophthalmol. 2006-11

[5]

Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.

Acta Ophthalmol. 2008-9

[6]

Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.

Can J Ophthalmol. 2007-4

[7]

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.

Am J Ophthalmol. 2006-10

[8]

Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.

Acta Ophthalmol Scand. 2007-5

[9]

Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization.

Acta Ophthalmol. 2008-2

[10]

Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.

Clin Exp Ophthalmol. 2008-7

引用本文的文献

[1]

Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.

Haematologica. 2025-5-1

[2]

Laser therapy for retinopathy in sickle cell disease.

Cochrane Database Syst Rev. 2022-12-12

[3]

Hemoglobinopathies: ocular manifestations in children and adolescents.

Ther Adv Ophthalmol. 2021-6-30

[4]

Gross anterior segment ischaemia following vitreoretinal surgery for sickle-cell retinopathy.

BMJ Case Rep. 2019-1-29

[5]

The past, present and future management of sickle cell retinopathy within an African context.

Eye (Lond). 2018-7-10

[6]

Inflammation in sickle cell disease.

Clin Hemorheol Microcirc. 2018

[7]

Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.

PLoS One. 2017-8-23

[8]

Laser therapy for retinopathy in sickle cell disease.

Cochrane Database Syst Rev. 2015-10-9

[9]

Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.

Haematologica. 2015-6

[10]

Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report.

Case Rep Ophthalmol Med. 2014

本文引用的文献

[1]

Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.

Acta Ophthalmol Scand. 2006-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献